BRIEF published on 11/14/2024 at 08:05, 7 days 6 hours ago Elumeo SE Maintains Stability in Challenging Q3/2024 Market Elumeo SE Q3 2024 Cost Management Gemstone Jewelry Consumer Confidence
PRESS RELEASE published on 11/14/2024 at 08:00, 7 days 6 hours ago elumeo SE continues to hold its own in Q3/2024 in a persistently difficult market en-vironment elumeo SE maintains stability in Q3/2024 despite challenging market conditions with sales almost steady at EUR 33.0 million and positive adjusted EBITDA of EUR 0.44 million Adjusted EBITDA Market Conditions Elumeo SE Sales Stability Q3/2024
BRIEF published on 10/25/2024 at 07:46, 27 days 6 hours ago Elumeo SE Announces Capital Increase with 250,000 New Shares European Market Capital Increase Elumeo SE Equity Ratio Gemstone Jewelry
PRESS RELEASE published on 10/25/2024 at 07:41, 27 days 6 hours ago EQS-Adhoc: elumeo SE: Capital increase of 250,000 shares at EUR 2 per share Berlin, 25 October 2024 elumeo SE resolves capital increase of 250,000 shares at EUR 2 per share to improve equity ratio. New shares issued to strategic investor. Dividend rights from 1 Jan 2024 Shares Capital Increase Elumeo SE Equity Ratio Dividend Rights
BRIEF published on 10/04/2024 at 09:44, 1 month 17 days ago Elumeo SE Revises 2024 Forecast Amid Economic Challenges Cost Reduction Elumeo SE 2024 Forecast Consumer Confidence Internationalization 2.0
PRESS RELEASE published on 10/04/2024 at 09:39, 1 month 17 days ago elumeo SE adjusts forecast for 2024 due to the economic situation – cost reduction program ahead of plan elumeo SE adjusts forecast for 2024 citing economic situation. Cost reduction program progresses ahead of schedule, impacting revenue, margin, and EBITDA outlook Revenue Cost Reduction Forecast Elumeo SE Economic Situation
BRIEF published on 10/04/2024 at 09:27, 1 month 17 days ago Elumeo SE Revises 2024 Financial Forecast Adjusted EBITDA Elumeo SE Sales Decline Financial Forecast Cost-cutting
PRESS RELEASE published on 10/04/2024 at 09:22, 1 month 17 days ago EQS-Adhoc: elumeo SE adjusts forecast for 2024 elumeo SE adjusts forecast for 2024, expecting a slight decline in sales, gross profit margin, and adjusted EBITDA. Measures in place to cut costs and increase savings Financial Year Forecast Adjustment Elumeo SE Sales Decline Cost-cutting Program
BRIEF published on 08/14/2024 at 08:05, 3 months 7 days ago Elumeo SE Maintains Profitability Amid Market Challenges in H1/2024 Profitability Elumeo SE Internationalization Cost Management H1 2024
PRESS RELEASE published on 08/14/2024 at 08:00, 3 months 7 days ago elumeo SE defies challenging market environment in H1/2024 and remains profitable on a quarterly and half-yearly basis elumeo SE remains profitable in H1/2024 despite challenging market environment, with slight sales growth and cost management measures. Forecast for 2024 confirmed Sales Growth Profitable Growth Elumeo SE Forecast 2024 Cost Management
Published on 11/21/2024 at 13:30, 36 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 36 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 6 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 6 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 6 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 31 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 51 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 8 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 46 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 21 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 21 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
